The German group is putting another €1.3bn into its Leaps by Bayer investment arm until the end of 2024 to support new companies that are "shifting core paradigms in the sectors of health and agriculture."

Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs. 

David Ricks says a consortium of companies will be needed to ensure enough doses of the successful candidates are available.

Although physicians still struggle with the best ways to treat patients suspected of having prostate cancer, a new group of genetic-based tests could provide new tools that will help improve diagnostic accuracy. These new biomarkers offer hope in reducing the number of patients who receive unnecessary treatment for cancers that are not actually present in their bodies and for those cancers not aggressive enough to cause harm.